HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study.

AbstractBACKGROUND:
Current consensus is that a combination of radiotherapy and chemotherapy may provide the optimal treatment for patients with unresectable rectal cancer. Raltitrexed has proven efficacy in the treatment of advanced colorectal cancer and has an acceptable toxicity profile. The aim of this phase I study was to determine the recommended dose of raltitrexed in combination with radiotherapy in patients with unresectable/recurrent rectal cancer.
PATIENTS AND METHODS:
Patients were treated with radiotherapy (25 fractions at 2.0 Gy per fraction) five times per week for 5 weeks. Raltitrexed was administered on days 1 and 22 at 2.0, 2.6 and 3.0 mg/m(2).
RESULTS:
A total of 20 patients were entered into the study. Dose-limiting toxicities were recorded in three of 20 patients following the first dose of raltitrexed; one patient at 2.6 mg/m(2) (grade 3 diarrhoea, grade 3 neutropenia and grade 2 pyrexia) and two patients at 3.0 mg/m(2) (one grade 3 neutropenia and one grade 4 diarrhoea). The most common non-haematological and haematological treatment-related adverse events were diarrhoea (11 of 20, two grade 3, one grade 4) and leukopenia (eight of 20, one grade 3, one grade 4), respectively.
CONCLUSIONS:
The recommended dose of raltitrexed in combination with radiotherapy for future studies is 2.6 mg/m(2).
AuthorsR D James, N Botwood, C C Vernon, P Price
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 14 Issue 4 Pg. 570-3 (Apr 2003) ISSN: 0923-7534 [Print] England
PMID12649103 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Quinazolines
  • Thiophenes
  • raltitrexed
Topics
  • Adult
  • Aged
  • Antimetabolites, Antineoplastic (administration & dosage, pharmacology)
  • Combined Modality Therapy
  • Diarrhea (chemically induced)
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy, pathology, radiotherapy)
  • Neutropenia (chemically induced)
  • Quinazolines (administration & dosage, pharmacology)
  • Rectal Neoplasms (drug therapy, pathology, radiotherapy)
  • Thiophenes (administration & dosage, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: